Study finds reduced Alzheimer’s incidence
A routine vaccine taken by millions each year may offer more than protection against seasonal illness. A large observational study published in Neurology found that older adults who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared with those who received a standard-dose shot.
The research, led by scientists at the McGovern Medical School at UTHealth in Houston, analyzed health data from approximately 165,000 adults aged 65 and older. Participants received either a high-dose or standard-dose flu vaccine, and researchers tracked Alzheimer’s diagnoses over roughly two years.
The findings showed that the high-dose vaccine was associated with nearly a 55% reduction in Alzheimer’s risk in this population. Previous research by the same team found that standard-dose flu vaccination was linked to about a 40% reduced risk over four years.
Why dose strength may matter
The high-dose influenza vaccine contains four times the antigen found in standard-dose versions. Antigens stimulate the body’s immune response, and researchers suggest that stronger protection against influenza infection may reduce severe illness and systemic inflammation.
Lower levels of systemic inflammation may, in turn, reduce neuroinflammation, a factor believed to contribute to neurodegeneration and cognitive decline.
The authors concluded that high-dose vaccination was associated with decreased incident dementia in adults aged 65 and older within a U.S. healthcare claims database. The protective effect appeared stronger and longer lasting in women, though both men and women showed reduced risk compared with standard-dose recipients.
Strengths and limitations
The study’s large sample size and comparative design between vaccinated groups were noted as strengths. However, researchers acknowledged several limitations.
One concern is “healthy-user bias,” meaning individuals who opt for high-dose vaccines may also engage in other health behaviors that reduce dementia risk. Additionally, reliance on insurance claims data may have led to misclassification of Alzheimer’s diagnoses.
The researchers emphasized that further studies are needed to better understand how vaccine dosage, immune response and long-term cognitive outcomes are connected. Future research could also explore whether vaccination influences disease progression after symptoms begin.
Context in the UK
According to the Alzheimer’s Society, an estimated 982,000 people in the UK are currently living with dementia, with projections rising to 1.4 million by 2040.
In England, more than 18.2 million patients registered with a GP received the flu vaccine during the 2024 to 2025 season. Vaccination rates included 70% of people over 65, 42% of pregnant women and 71% of care home residents.
Understanding Alzheimer’s symptoms
Alzheimer’s disease is the most common cause of dementia. Early symptoms typically include memory lapses, difficulty recalling recent events and trouble finding words. As the condition progresses, individuals may experience confusion, mood changes, impaired judgment, language problems and behavioral shifts.
While the new findings do not prove that high-dose flu vaccination directly prevents Alzheimer’s, they add to growing evidence that immune health and inflammation may play a role in long-term cognitive outcomes.